| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/01/2010 | CA2737912A1 Fused ring thiophene dyes for imaging and therapy |
| 04/01/2010 | CA2737645A1 Compounds which selectively modulate the cb2 receptor |
| 04/01/2010 | CA2737639A1 Compounds which selectively modulate the cb2 receptor |
| 04/01/2010 | CA2736939A1 Method of metronomic dosing with camptothecin prodrugs ( e.g.peg-irinotecan ) |
| 04/01/2010 | CA2736539A1 Compound for local deletion of tumors |
| 04/01/2010 | CA2734472A1 2-[1h-benzimidazol-2(3h)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3h)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors |
| 03/31/2010 | EP2169073A1 Vector for the preparation of immunotherapeutical compositions |
| 03/31/2010 | EP2169060A1 Novel polypeptide useful for diagnosis and treatment of cancer |
| 03/31/2010 | EP2168984A1 Human antibodies that bind human IL-12 and methods for producing |
| 03/31/2010 | EP2168977A1 Vaccine antigen capable of inducing cross-reacting and neutralizing antibody against high-risk-type human papillomavirus |
| 03/31/2010 | EP2168972A2 Preparation and use of carbohydrate-based ring structures with antimicrobial and cytostatic activity |
| 03/31/2010 | EP2168968A1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
| 03/31/2010 | EP2168966A1 Bicycloaniline derivative |
| 03/31/2010 | EP2168964A1 Azaindole-indole coupled derivatives, preparation methods and uses thereof |
| 03/31/2010 | EP2168958A1 Isoindole-Imide Compounds, Compositions And Uses Thereof |
| 03/31/2010 | EP2168948A1 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors |
| 03/31/2010 | EP2168599A1 Cancer remedy containing antibody against peptide encoded by exon-17 of periostin |
| 03/31/2010 | EP2168598A1 Method of Treatment Using Ligand-Immunogen Conjugates |
| 03/31/2010 | EP2168594A1 Treating neoplasms with neurotoxin |
| 03/31/2010 | EP2168588A1 An extract of rehmannia glutinasa libosch. for reducing blood sugar, reducing blood fat, treating leukemia and preparation method and uses thereof |
| 03/31/2010 | EP2168583A1 Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| 03/31/2010 | EP2168582A1 Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines |
| 03/31/2010 | EP2168581A2 Stable polymorph of N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof |
| 03/31/2010 | EP2168578A2 2-Amido-Thiazole-Based Compounds Exhibiting ATP-Utilizing Enzyme Inhibitory Activity, and Compositions, and Uses Thereof |
| 03/31/2010 | EP2168577A1 Drug having effect of promoting hepatocyte growth |
| 03/31/2010 | EP2168574A1 Compound for local deletion of tumors |
| 03/31/2010 | EP2168440A1 Equol-containing extract, method for production thereof, method for extraction of equol, and equol-containing food |
| 03/31/2010 | EP2167662A2 Pharmaceutical compounds comprising abasic oligonucleotides |
| 03/31/2010 | EP2167661A2 Rnai mediated knockdown of numa for cancer therapy |
| 03/31/2010 | EP2167649A1 Immunotherapy for hematological malignancies |
| 03/31/2010 | EP2167544A2 Monoclonal antibody directed against the human ldl receptor |
| 03/31/2010 | EP2167542A1 Neutralizing monoclonal antibody against human dll4 |
| 03/31/2010 | EP2167541A2 The ed-a antigen of fibrinogen is associated with the neovasculature of tumour metastases |
| 03/31/2010 | EP2167521A1 ONCOGENIC ALL-1 FUSION PROTEINS FOR TARGETING DROSHA-MEDIATED microRNA PROCESSING |
| 03/31/2010 | EP2167504A2 Thiadiazole modulators of pkb |
| 03/31/2010 | EP2167497A2 Heterocyclic compounds useful as raf kinase inhibitors |
| 03/31/2010 | EP2167492A2 Novel amide derivative for inhibiting the growth of cancer cells |
| 03/31/2010 | EP2167480A2 Cationic lipids compositions and methods for enhancing immune responses to vaccines |
| 03/31/2010 | EP2167465A1 Indolinone derivatives and their use in treating disease-states such as cancer |
| 03/31/2010 | EP2167459A1 Novel triazine compounds for treatment of cancer |
| 03/31/2010 | EP2167138A2 Mir-34 regulated genes and pathways as targets for therapeutic intervention |
| 03/31/2010 | EP2167128A2 Engineered anti-alpha v- integrin hybrid antibodies |
| 03/31/2010 | EP2167125A1 An antibody specific for the tn antigen for the treatment of cancer |
| 03/31/2010 | EP2167118A1 Transmembrane prostatic acid phosphatase |
| 03/31/2010 | EP2167113A2 Neuroplastin derived peptides |
| 03/31/2010 | EP2167103A1 Self-assembling amphiphilic polymers as anticancer agents |
| 03/31/2010 | EP2167092A2 Quinazoline derivatives as pi3 kinase inhibitors |
| 03/31/2010 | EP2166859A1 Quinazoline salt compounds |
| 03/31/2010 | EP2166846A1 Inhibitors of janus kinases |
| 03/31/2010 | EP1735311B1 Beta-carbolines useful for treating inflammatory disease |
| 03/31/2010 | EP1630165B1 [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-2-YLUREA DERIVATIVE AND USE THEREOF |
| 03/31/2010 | EP1530724B1 Diagnosis and prevention of cancer cell invasion |
| 03/31/2010 | EP1301194B1 Essential oil combination and therapeutic uses thereof |
| 03/31/2010 | EP1244460B1 Use of dipyridinium compounds for treating a disease characterized by proliferating cells containing nitric oxide synthase |
| 03/31/2010 | EP1223923B1 Unsaturated aryl sulfones for protecting normal cells from cytotoxicity of chemotherapeutic agents |
| 03/31/2010 | EP1194168B1 Methods and products for manipulating uncoupling protein expression |
| 03/31/2010 | EP1107989B1 Expression and export of angiostatin and endostatin as immunofusins |
| 03/31/2010 | CN101688183A Cancerous disease modifying antibodies |
| 03/31/2010 | CN101688179A Recombinant protein production in avian ebx r cells |
| 03/31/2010 | CN101687931A an anti-cancer cytotoxic monoclonal antibody |
| 03/31/2010 | CN101687930A Chimeric and humanized anti-CD44 antibodies that mediate cancer cell cytotoxicity |
| 03/31/2010 | CN101687929A Monoclonal antibodies against claudin-18 for treatment of cancer |
| 03/31/2010 | CN101687924A anti-muc17 antibody |
| 03/31/2010 | CN101687923A The ed-a antigen of fibrinogen associated with the neovasculature of tumour metastases |
| 03/31/2010 | CN101687900A Double-stranded locked nucleic acid compositions |
| 03/31/2010 | CN101687881A Fused heterocyclic compounds useful as modulators of nuclear hormone receptor function |
| 03/31/2010 | CN101687874A Pyrrolotriazine kinase inhibitors |
| 03/31/2010 | CN101687866A Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor |
| 03/31/2010 | CN101687863A Amino-thiazolyl- pyrimidine derivatives and their use for the treatment of cancer |
| 03/31/2010 | CN101687854A Compounds and compositions as C-KIT and PDGFR kinase inhibitors |
| 03/31/2010 | CN101687853A Pyrimidine derivatives and compositions as C-KIT and PDGFR kinase inhibitors |
| 03/31/2010 | CN101687840A Benzimidazole amido derivatives as kinase inhibitors |
| 03/31/2010 | CN101687838A Pyrrolo [3, 2-a] pyridine derivatives for inhibiting ksp kinesin activity |
| 03/31/2010 | CN101687835A Hydroxy sulfonate of quinone compounds and their uses |
| 03/31/2010 | CN101687821A protein kinase inhibitors and methods for using thereof |
| 03/31/2010 | CN101687807A 1-benzylpyrazole derivatives, preparation thereof and therapeutic use thereof |
| 03/31/2010 | CN101687798A Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof |
| 03/31/2010 | CN101687049A Immunocytokines for cancer treatment in combination with chemotherapeutic agents |
| 03/31/2010 | CN101687047A Targeted split biomolecular conjugates for the treatment of diseases, malignancies and disorders, and methods of their production |
| 03/31/2010 | CN101687039A Engineered anti-alpha v- integrin hybrid antibodies |
| 03/31/2010 | CN101687037A Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates |
| 03/31/2010 | CN101687036A CHK1 inhibitors with b cell depleting antibodies for the treatment of hematologic malignancies |
| 03/31/2010 | CN101687034A Remedy for chemotherapy-resistant cancer containing hla class i-recognizing antibody as the active ingredient and use of the same |
| 03/31/2010 | CN101687016A Activin-actriia antagonists and uses for promoting bone growth in cancer patients |
| 03/31/2010 | CN101687014A compositions and methods for treating pathologic angiogenesis and vascular permeability |
| 03/31/2010 | CN101687001A 植物提取物及其治疗用途 Plant extracts and therapeutic use |
| 03/31/2010 | CN101686984A Pharmaceutical combination of nsaid and prostaglandin compound |
| 03/31/2010 | CN101686981A diazo bicyclic smac mimetics and the uses thereof |
| 03/31/2010 | CN101686975A Antitumour combinations containing a vegf inhibiting agent and irinotecan |
| 03/31/2010 | CN101686973A Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles |
| 03/31/2010 | CN101686971A Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies |
| 03/31/2010 | CN101686970A Synergistic combination of anthranilamide pyridinureas and benzamide derivatives |
| 03/31/2010 | CN101686967A Pyrazolo pyridine derivatives as nadph oxidase inhibitors |
| 03/31/2010 | CN101686965A Compositions comprising (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases |
| 03/31/2010 | CN101686960A Methods and compositions for contributing to the treatment of cancers |
| 03/31/2010 | CN101684499A Compositions and methods for detection and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene |
| 03/31/2010 | CN101684477A Novel tumor target gene therapy system based on gland virus replication and recombination |
| 03/31/2010 | CN101684472A Recombinant fusion proteins containing p53 genes, recombinant and application thereof |
| 03/31/2010 | CN101684467A Application of double-stranded small interfering RNA of PEG10 gene in preparation of medicaments for treating or preventing liver cancer |
| 03/31/2010 | CN101684466A Application of double-stranded small interfering RNA of PEG10 gene in preparation of medicaments for treating or preventing liver cancer |